April 15 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX :
* PARADIGM PHASE 2B TRIAL MEETS KEY SECONDARY ENDPOINTS IN OSTEOARTHRITIS OF KNEE
April 15 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX :
* PARADIGM PHASE 2B TRIAL MEETS KEY SECONDARY ENDPOINTS IN OSTEOARTHRITIS OF KNEE